DarioHealth Corp. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed on July 26, 2017, covering events that occurred on July 25, 2017. DarioHealth Corp., an emerging growth company incorporated in Delaware with principal offices in Israel, reported significant executive compensation updates and a new officer appointment.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, or liquidity metrics. The document focuses exclusively on executive employment terms.
Material Changes and Executive Actions
- CEO Compensation Update: An Amended and Restated Employment Agreement was executed with CEO Erez Raphael. His monthly salary remains NIS 80,000 (approx. $22,415). He is eligible for an annual bonus of up to 60% of his base salary. The agreement term extends to December 31, 2020.
- CEO Severance Terms: In the event of termination without cause or for "good reason," Mr. Raphael is entitled to 24 months of base salary plus statutory severance. If termination occurs in the final year of the term, the entitlement reduces to 12 months.
- Salary Waiver Program: Mr. Raphael intends to waive approximately 45% of his 2017 cash salary in exchange for company stock, continuing a program from the prior fiscal year.
- New Officer Appointment: Dror Bacher was appointed Chief Operating Officer (COO). He previously served as VP of R&D and Operations since 2013.
- COO Compensation: Mr. Bacher's annual base salary increases to NIS 59,000 (approx. $16,531), effective August 2017. He received 10,000 shares of common stock and 10,000 options (exercise price $2.46) vesting over three years.
- COO Salary Waiver: Mr. Bacher expects to waive approximately 24% of his 2017 cash salary in exchange for stock.
Outlook, Risks, and Contingencies
The filing outlines standard non-competition and non-solicitation provisions for both executives (one year for the CEO, twelve months for the COO). No specific financial risks, contingencies, or forward-looking guidance regarding business performance were disclosed in this report.
Key Facts for Investor Verification
- Verify the total number of shares issued to Mr. Bacher and the impact on total share count.
- Confirm the valuation of the stock options granted to Mr. Bacher for expense recognition purposes.
- Review the full text of the Amended Employment Agreements (Exhibits 10.1 and 10.2) for detailed termination triggers and "good reason" definitions.
- Monitor the company's cash burn rate given the continuation of salary-for-stock waivers, which may indicate liquidity constraints.